At a glance

ClinicalIndex Comparison Record

Phase 4Completed· 99 enrolled

Drug / intervention

Sugammadex, Neostigmine, Salinedrug

Likely dose

Sugammadex, Neostigmine, Saline 0.0625 mg/kgfrom record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00895609

NCT00895609Phase 4Completed

Compare CT.gov

Dose Finding Study for Sugammadex and Neostigmine at Residual Neuromuscular Blockade (T4/T1 = 0.5)

Technical University of Munich·interventional·Posted May 8, 2009·Updated Mar 19, 2013

In Brief

A Phase 4 clinical trial evaluating Sugammadex, Neostigmine, Saline for Neuromuscular Block. Completed, enrolled 99 participants across 1 site.

Detailed Summary

This study is designed to compare recovery times after reversal of a residual neuromuscular block (TOF-ratio 0.5) with different doses of either neostigmine or sugammadex.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsNeuromuscular Block

CountriesGermany

Collaborators--

Timeline

Phase 4CompletedFinished

200920102011201220132014201520162017201820192020202120222023202420252026

Enrollment StartMar 2009

First PostedMay 2009

Primary CompletionAug 2009

TodayJul 2026

First PostedMay 8, 2009

Enrollment StartMar 1, 2009

Primary CompletionAug 1, 2009

TodayJul 2, 2026

Enrollment to primary: 5 monthsPosted 17.2 years ago

Interventions

Sugammadex, Neostigmine, Salinedrug

Single intravenous injection of either: Sugammadex 0.0625 mg/kg (Sgx 0.0625) Sugammadex 0.125 mg/kg (Sgx 0.125) Sugammadex 0.25 mg/kg (Sgx 0.25) Sugammadex 0.5 mg/kg (Sgx 0.5) Sugammadex 1.0 mg/kg (Sgx 1.0) Neostigmine 5 mg/kg (Neo 5) Neostigmine 8 mg/kg (Neo 8) Neostigmine 15 mg/kg (Neo 15) Neostigmine 25 mg/kg (Neo 25) Neostigmine 40 mg/kg (Neo 40) Saline 0.9% (Saline)